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Abstract
Objectives: To describe the design of a clinical trial testing the hypothesis that children randomized to tight
glycemic control with intensive insulin therapy after cardiac surgery will have improved clinical outcomes
compared to children randomized to conventional blood glucose management.
Design: Two-center, randomized controlled trial.
Setting: Cardiac ICUs at two large academic pediatric centers.
Patients: Children from birth to those aged 36 months recovering in the cardiac ICU after surgery with
cardiopulmonary bypass.
Interventions: Subjects in the tight glycemic control (intervention) group receive an intravenous insulin
infusion titrated to achieve normoglycemia (target blood glucose range of 80–110 mg/dL; 4.4–6.1 mmol/L).
The intervention begins at admission to the cardiac ICU from the operating room and terminates when the
patient is ready for discharge from the ICU. Continuous glucose monitoring is performed during insulin
infusion to minimize the risks of hypoglycemia. The standard care group has no target blood glucose range.
Measurements and Main Results: The primary outcome is the development of any nosocomial infection
(bloodstream, urinary tract, and surgical site infection or nosocomial pneumonia). Secondary outcomes
include mortality, measures of cardiorespiratory function and recovery, laboratory indices of nutritional
balance, immunologic, endocrinologic, and neurologic function, cardiac ICU and hospital length of stay, and
neurodevelopmental outcome at 1 and 3 yrs of age. A total of 980 subjects will be enrolled (490 in each
treatment arm) for sufficient power to show a 50% reduction in the prevalence of the primary outcome.
Conclusions: Pediatric cardiac surgery patients may recognize great benefit from tight glycemic control in the
postoperative period, particularly with regard to reduction of nosocomial infections. The Safe Pediatric
Euglycemia after Cardiac Surgery trial is designed to provide an unbiased answer to the question of whether
this therapy is indeed beneficial and to define the associated risks of therapy.
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Abstract
Objective—To describe the design of a clinical trial testing the hypothesis that children
randomized to tight glycemic control with intensive insulin therapy after cardiac surgery will have
improved clinical outcomes compared to children randomized to conventional blood glucose
management
Design—Two-center, randomized controlled trial
Setting—Cardiac intensive care units (CICUs) at two large academic pediatric centers
Patients—Children from birth-36 months recovering in the CICU after surgery with
cardiopulmonary bypass
Interventions—Subjects in the tight glycemic control (intervention) group receive an
intravenous insulin infusion titrated to achieve normoglycemia (target blood glucose range of 80–
110 mg/dL; 4.4–6.1 mmol/L). The intervention begins upon admission to the CICU from the
operating room and terminates when the patient is ready for discharge from the intensive care unit.
Continuous glucose monitoring is performed for the duration of insulin infusion to minimize the
risks of hypoglycemia. The standard care group has no target blood glucose range.
Measurements and Main Results—The primary outcome is the development of any
nosocomial infection (bloodstream, urinary tract, and surgical site infection, or nosocomial
pneumonia). Secondary outcomes include mortality, measures of cardiorespiratory function and
recovery, laboratory indices of nutritional balance, immunologic, endocrinologic, and neurologic
function, CICU and hospital length of stay, and neurodevelopmental outcome at 1 and 3 years of
age. A total of 980 subjects will be enrolled (490 in each treatment arm) for sufficient power to
show a 50% reduction in the incidence of the primary outcome.
Conclusions—Pediatric cardiac surgical patients may recognize great benefit from tight
glycemic control in the postoperative period, particularly in regard to reduction of nosocomial
infections. The SPECS trial is designed to provide an unbiased answer to the question of whether
this therapy is indeed beneficial and to define the associated risks of therapy.
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Introduction
Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose
(BG) levels, occurs frequently in critically ill patients. Previously thought to be an adaptive
response to illness as a means of increasing energy supply to metabolically stressed systems,
stress hyperglycemia was infrequently treated in non-diabetic patients. Over the last two
decades there has been a new appreciation for the negative outcomes associated with
hyperglycemia in the intensive care unit. Up to 90% of pediatric cardiac surgical patients
requiring cardiopulmonary bypass (CPB) are at risk for hyperglycemia in the perioperative
period 90% [1–4] and several retrospective analyses suggest an association between
hyperglycemia and perioperative morbidity and mortality in children recovering from
cardiac surgery [2, 3, 5]. On the basis of several investigations [6–8] including the landmark
study by Van den Berghe and colleagues [9], tight glycemic control (TGC) protocols with
intensive insulin therapy were instituted in many adult critical care units to ameliorate the
effects of stress hyperglycemia. Particularly in adult cardiac surgical patients, glycemic
control led to improvements in mortality, intensive care length of stay, and benefits in
multiple organ systems, most notably decreasing intravenous device, bloodstream, and
surgical site infections by nearly 50% [7, 9]. However, in part because of subsequent trials
challenging these single-center findings [10–13] and benefits in the original Van den Berghe
study being limited to certain subgroups, pediatric intensivists have not widely adopted the
practice of TGC [14–16].
Though there are now several reports of glycemic control protocols being used in critically
ill pediatric patients [17–19], questions remain over the optimal BG target range for these
patients, and the risks associated with treatment-induced hypoglycemia. In the only previous
randomized trial evaluating the benefit of TGC in pediatric cardiac surgical patients [20],
children in the intensive insulin therapy arm derived several benefits including reduced
inflammation, vasoactive support, infections, length of intensive care stay and mortality.
However, regular use of this therapeutic strategy in the pediatric cardiac intensive care unit
is still rare because of generalizability concerns from the mixed critical care study
population and the reported rate of hypoglycemia; the intervention group in the pediatric
trial had a 25% incidence of severe hypoglycemia (<40 mg/dL; 2.2 mmol/L) with a 45%
incidence rate in infants. Further study is necessary to devise a TGC protocol with an
acceptable risk-benefit profile, and within that context to confirm the clinical benefits in the
pediatric critically-ill population.
We designed a clinical trial to target the patient group most likely to benefit from TGC using
the most highly advanced FDA-approved continuous glucose monitoring technology to
minimize the risk of hypoglycemia associated with the intervention. This report describes
the design and rationale for this active, National Institutes of Health (NIH)-funded (R01
HL088448), multisite, randomized controlled trial. The study, entitled Safe Pediatric
Euglycemia after Cardiac Surgery (SPECS; NCT00443599), compares outcomes of infants
and young children treated in the cardiac intensive care unit (CICU) after cardiac surgery
with TGC and continuous glucose monitoring to those who receive conventional BG
management.
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Materials and Methods
Study overview
This trial tests the primary hypothesis that children randomized to TGC with intensive
insulin therapy in the CICU post-operatively will have fewer nosocomial infections
compared to children randomized to conventional BG management. The TGC group
receives an intravenous insulin infusion titrated to achieve normoglycemia (target BG range
of 80–110 mg/dL; 4.4–6.1 mmol/L). The standard care (STD) group has no target range for
BG management and patients are treated according to the preference of the attending
physician. Our choice of target range for TGC was higher than a recent large pediatric ICU
trial that implemented TGC based on age-specific fasting BG values [20]. Hypoglycemia in
association with fasting is accompanied by increased production of ketones and free fatty
acids as available alternative fuels to the brain. However, TGC induced by insulin
suppresses lipolysis resulting in reduced concentrations of these alternative fuels to the
brain.
The concept for this study was developed by investigators at Children’s Hospital Boston
(CHB) which serves as the coordinating center, with patients also being enrolled at the
University of Michigan C.S. Mott Children’s Hospital (CSM). Study protocol modifications
are developed collaboratively. We plan to enroll 980 patients randomly assigned to one of
these two treatment groups. Study enrollment began in 2008 and will conclude in mid-2012.
A study flow chart is shown in Figure 1. Approval from the two institutional review boards
(IRB) was obtained prior to enrollment.
Subject Selection
Subject selection criteria were defined to ensure a relatively homogeneous study population
at highest risk for post-operative hyperglycemia and nosocomial infection, and in which the
safety and functionality of study monitoring equipment was previously validated [21].
Inclusion and exclusion criteria are shown in Table 1. Potential subjects are approached by a
member of the study team in the outpatient surgical pre-operative clinic or on an inpatient
floor. Patients who do not consent to participate are treated according to usual practice by
the clinical team, led by the attending CICU physician, occasionally including therapy for
glycemic control.
Study Protocol
Continuous glucose monitoring—The study protocol begins after induction of
anesthesia and prior to surgical incision with placement of the subcutaneous sensor
wirelessly paired with the continuous glucose monitor (CGM; Guardian® REAL-Time
device, Medtronic Minimed, Northridge, CA). Prior to the study, the CGM was tested in a
study of critically-ill pediatric cardiac surgical patients less than 3 years of age; it functioned
well compared to glucose measurement with a blood gas analyzer in a wide range of clinical
states (mean absolute relative difference of 18% and a Pearson correlation coefficient of 0.8)
[21]. Other authors have reported similar results [22, 23]. The sensor is inserted with
minimal discomfort into the lateral thigh of the subject and communicates wirelessly to a
pager-sized monitor every five minutes. The monitor records and displays a BG estimate
every five minutes, and alarms when the BG drops below manually set limits. This device is
FDA-approved for patients seven years of age or older, and was approved by local IRBs for
the age range targeted in this trial as a non-significant risk device. CGM values are
confirmed when necessary with an arterial blood sample measured with bedside meters
available at the respective institutions (SureStep®Flexx®, LifeScan, at CHB and ACCU-
CHECK® Inform, Roche, at CSM). CGM calibration is performed every 6 hours using these
glucometers.
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The sensor alarm is set to notify the bedside nurse of actual or impending hypoglycemia
(defined as a BG concentration < 60 mg/dL; 3.3 mmol/L) in both study groups. After an
early review of sensor performance, the alarm threshold was raised from 60 mg/dL to 70
mg/dL (3.3 to 3.9 mmol/L) and a 15 minute prediction setting was activated [24]. Sensors
are activated upon admission to the CICU and are replaced every 72 hours according to the
manufacturer’s guidelines.
CICU therapy: Tight glycemic control (TGC) vs. Standard of Care (STD)—
Patients are randomized after initiation of CPB using sealed opaque envelopes generated by
the CHB Clinical Research Program containing the group assignment for each patient based
on a serially numbered sequence using permuted blocks with random block sizes. Patients
are block-randomized by center. For those patients randomized to TGC, the glycemic
control protocol begins after admission to the CICU and assumption of care by the CICU
attending physician and bedside nurse. The insulin infusion (0.2 units regular human insulin
per 1 mL 0.9% NaCl) is left to dwell in dedicated IV tubing for ≥16 hours to saturate insulin
binding sites prior to administration. An initial whole BG measurement is made within 60
minutes of CICU admission on a hospital-approved glucose meter and the CGM is
calibrated at this time. All BG measurements are performed using 0.05 mL samples obtained
from an indwelling arterial catheter placed for standard post-operative monitoring and blood
sampling. The study protocol is suspended or discontinued when there is no indwelling
arterial catheter. An attachment [VAMP Jr. (Edwards Lifesciences, LLC, Irvine, CA) or
Neonatal SafeSet (ICU Medical Inc., San Clemente, CA)] to the arterial catheter tubing
allows for a closed-line system, minimal blood waste, and standardized sampling. Insulin
therapy is initiated and continued for TGC subjects if the glucose concentration exceeds or
is expected to exceed 110 mg/dL (6.1 mmol/L) within 30 minutes as predicted by the
treatment algorithm (see below).
Insulin is administered only when there is a functional CGM in place; in the case of a
temporary CGM malfunction, BG is measured every hour until a new sensor can be placed.
Insulin is always infused along with 0.9% NaCl carrier running at 1 mL/hr, preferentially
through a dedicated peripheral intravenous catheter. The lumen of a central venous or
intracardiac catheter can be used if there is compatibility with other infusions and the route
is judged to be safe by the bedside clinicians. The protocol is suspended at any point if there
is inadequate venous access to administer the insulin infusion; the protocol can be re-started
if venous access becomes available, but catheters are never placed solely to administer the
study protocol.
The dose of insulin is titrated according to a paper-based algorithm translated into a
Microsoft Excel® spreadsheet displayed on a dedicated laptop computer at the bedside. BG
concentration is monitored by the CGM and a hospital-approved glucose meter at a
clinically-indicated frequency determined by the infusion algorithm. Glucose meter checks
occur at least as frequent as every two hours during insulin infusion, and every six hours
when insulin is not being infused. Meter checks are required 1 hour after any increase in the
insulin infusion rate, 30 minutes after any algorithm-recommended dextrose bolus, and at
any time the sensor alarms for hypoglycemia.
The goal of post-operative glycemic control in the TGC group is a BG concentration of 80–
110 mg/dL (4.4–6.1 mmol/L). This target was determined from previous adult studies
demonstrating the greatest benefit in patients with true normoglycemia as opposed to
moderate hyperglycemia [25]. Literature published since the start of SPECS has suggested
different optimal target ranges for BG management in adults [12]. However, as there are no
equivalent data in children, we continued our strategy of comparing a normoglycemic BG
target to STD.
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The insulin infusion algorithm has been described previously [24, 26]. A summary of the
proportional, integral, and derivative components is depicted in Box 1. The algorithm
calculates a recommended intravenous insulin infusion rate as the sum of these components
factoring the present BG level, the patient’s BG profile and insulin requirements over time,
and the rate of change of the BG level. If the BG level is falling faster than desired, a dose
reduction is recommended by the algorithm; if BG increases at a stable dose the infusion
rate is increased slightly. When the BG level drops or is anticipated to drop below 60 mg/dL
(3.3 mmol/L) the algorithm recommends suspension of insulin delivery and administration
of an IV dextrose bolus. A minimum change in insulin delivery is set to prevent frequent
minor adjustments and necessitating excessive blood draws.
Box 1
Summary of insulin infusion algorithm components
Proportional (P) Present – the difference between measured and target glucose
Integral (I) Past – area under the curve between measured and target glucose
Derivative (D) Future – Rate of change in glucose level
The dose of insulin is actively maintained or titrated hourly by the bedside nurse according
to recommendations from the algorithm. Insulin dose changes are only made in response to a
BG value obtained with a glucose meter; no changes are made in response to values reported
by the CGM which are used primarily to demonstrate stable BG or to alert the bedside
clinician to perform more frequent BG measurement (for instance if it senses impending or
actual hypoglycemia). The protocol can be interrupted if it is deemed unsafe for any period
of time by the investigators or the clinical team. For example, during sterile procedures
where it would be difficult for the nurse to perform the necessary study functions, insulin
infusions are typically suspended. The protocol is suspended when patients leave the CICU
for any reason. All protocol deviations are recorded and tracked.
In patients randomized to the STD group, the CGM is placed to serve as a hypoglycemic
alarm to give all subjects some benefit from participation. Audible alarms are enabled only
for detection of hypoglycemia; sensor-measured glucose values are not reported to the
bedside clinicians. Hyperglycemia in STD subjects is treated at the discretion of the
attending intensivist. Typical practice at each institution for treatment of hyperglycemia is to
initiate insulin if glucosuria is present, or if the BG concentration is persistently >200–300
mg/dL (11.1–16.7 mmol/L). There is no unit-based clinical protocol at either institution for
glycemic control, and insulin therapy for this indication is rarely utilized. If the treating
clinician chooses to initiate insulin therapy, CGM is not used to guide treatment decisions
although the alarm function for hypoglycemia remains activated. The protocol is not altered
in any way for either treatment arm if the patient is on extracorporeal circulatory support;
CGMs are inserted and replaced according to the protocol.
All patients in both groups otherwise receive the institution’s standard anesthetic and
surgical management [27], as well as standard postoperative care; the protocol does not
restrict use of glucocorticoids, vasoactive support, nutritional support, or antibiotics peri-
operatively, nor does it change infection monitoring, control, and treatment in the CICU.
Neither study site has a protocol for therapeutic hypothermia after cardiac arrest. The study
protocol ends in either group if one of the following occurs: removal of arterial catheter(s),
transfer out of the CICU, or if the subject remains in the CICU beyond 30 days after the
index procedure. Insulin infusions are discontinued if the patient starts ad lib feeds by mouth
or bolus feeds via a nasogastric tube. In STD subjects, CGM occurs for at least the first three
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post-operative days. Monitoring is discontinued after 72 hours if the patient is judged to be
clinically stable with no recorded hypoglycemia (BG <60 mg/dL; 3.3mmol/L) for at least 12
hours. The protocol is not resumed if study patients require re-admission to the CICU.
Study Measurements and Follow-up
Baseline, intraoperative, and postoperative clinical and laboratory data are collected daily by
study personnel. Postoperative data collection is continued until either the subject is
designated by the clinical team for transfer out of the CICU, or after 30 days from the index
procedure. Subjects are monitored for infections attributable to the CICU for 48 hours after
leaving the CICU. Families of subjects are contacted at 30 days and 1 year after the index
procedure to monitor hospital readmission and development of surgical site infection.
Families invited to return for neurodevelopmental testing when participants reach 1 and 3
years of age. This testing is completed within 8 weeks of the patient’s birthday, and occurs
no less than 6 weeks after a major hospitalization or operative procedure.
Trial Outcomes
The primary outcome of the SPECS trial is the development of nosocomial infection
(bloodstream infection, urinary tract infection, nosocomial/ventilator-associated pneumonia,
or surgical site infection) according to Centers for Disease Control definitions as of 2005
[28]. The infection rate will be reported as infections per 1,000 patient days in the CICU.
Infections are adjudicated by the local infection control clinicians at each institution who are
not part of the study team and are blinded to the subjects’ treatment group assignment.
Secondary outcomes are shown in Table 2 and include mortality, measurements of organ
function, nutritional data, CICU length of stay, and neurodevelopmental outcomes. The
standardized test battery used to measure neurodevelopmental outcomes is shown in Table
3.
Statistical Analysis
All primary analyses will be performed on an intention-to-treat basis. Based on adult data,
we hypothesize that TGC will lead to a 50% decrease in nosocomial infection rate. Pre-trial
nosocomial infection rate (February through August of 2005) in the population of interest at
CHB was 11.4 infections per 1,000 CICU days, and 10.4 per 1,000 days at CSM. Using
these values and a stratified Poisson-based power calculation with a 0.05 two-sided
significance level, we estimate 80% power to detect a 50% difference in nosocomial
infection rate between the TGC and STD groups when the sample size is 490 subjects in
each treatment arm (980 total). There was no accounting for potential patient withdrawals in
this calculation and all patients will be analyzed regardless of protocol violations.
Nosocomial infections in post-operative cardiac surgery patients may be influenced by
factors not affected by the intervention of TGC. In adult medical ICU patients, prevention of
morbidity was seen in all patients randomized to TGC, but mortality reduction attributable
to TGC was seen only in those patients whose ICU stay lasted for more than 2 days [8].
Thus, an a priori sub-group analysis of patients admitted to the ICU for 3 or more days after
surgery will be performed to explore the effect of TGC in patients with an extended ICU
stay. In addition, we will examine the impact of procedure complexity on outcomes by
adjusting for RACHS-I score (Risk Adjustment for Congenital Heart Surgery-I), a
consensus-based method to adjust for case-mix differences [29].
Study Oversight
An independent data and safety monitoring board (DSMB) monitors the trial for adverse
events, adherence to study protocol, and potential early stopping. A planned interim analysis
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will be performed at the midpoint of the study to determine whether the intervention is
associated with increased mortality or increased adverse events, and whether a highly
significant benefit of one group (efficacy) or extreme lack of difference (futility) emerges
before the planned end of the study [30]. In addition, DSMB meetings occur at regular 6
month intervals to review emerging data on TGC in other populations. Changes to the study
protocol will be recommended by the DSMB based on their independent review.
Discussion
Rationale for Choice of Outcome Measures
Mortality, the common primary outcome in adult ICU studies, was not a plausible outcome
in this study. With an expected 3–5% mortality rate in our study population, demonstrating a
significant reduction would require a much larger sample size for equivalent power.
Furthermore, mortality in this population is largely driven by procedural complexity and not
modifiable by TGC. For these reasons we, like many other pediatric critical care trialists,
chose an alternative important outcome.
Pediatric cardiac surgical patients are at particular risk for nosocomial infections; in addition
to hyperglycemia, children experience a state of immunoparalysis after CPB, incur
significant tissue damage, are exposed to multiple invasive monitoring catheters, and
undergo ischemia-reperfusion injury. Published [31] and unpublished local data demonstrate
that the risk is highest among children under 3 years of age who undergo the most complex
procedures necessitating longer recovery in the CICU, making this population ideal
candidates for this trial. In addition to complicating and prolonging the CICU stay,
nosocomial infections result in increased healthcare expenditures. The additional average
direct cost of a nosocomial bloodstream infection for patients in an academic tertiary care
center pediatric ICU has been estimated at $39,219 [32]. Thus, reducing the incidence of
nosocomial infections will result in clinical and cost benefits.
Analysis of clinical trials involving TGC suggests that control of the BG level, rather than
the insulin dose, leads to the clinical improvements seen in sepsis and multi-organ system
failure [6, 33]. Several potential mechanisms explain the deleterious effects of
hyperglycemia on normal immune function including upregulation of pro-inflammatory
cytokines IL-8 and NF-κB, impairment of humoral and cellular immunity [34], and
diminishing wound healing by protein glycosylation and stimulation of collagenase activity
[35].
The theoretical advantages of perioperative insulin therapy after cardiac surgery may not be
strictly limited to control of hyperglycemia and immunomodulation. Insulin inhibits pro-
inflammatory mediators and enhances nitric oxide synthase [36]. Insulin favorably alters
myocardial metabolism towards glycolysis under ischemic conditions [37], reduces
oxidative stress after ischemia-reperfusion [38], and improves calcium handling in the
sarcoplasmic reticulum [39]. These benefits may play an important role in myocardial
recovery after CPB and shorten duration of vasoactive support, time to negative fluid
balance, and duration of mechanical ventilation and intensive care stay.
As mortality after pediatric cardiac surgery has decreased substantially over the past three
decades [40], neurodevelopmental outcome has become an increasingly important measure
by which to compare perioperative practices. Neurodevelopmental outcomes are particularly
germane to the study of TGC in pediatric patients given the concern about potential
deleterious effects of hypoglycemia on the developing brain. Previous adult and pediatric
studies of TGC have been plagued by high rates of hypoglycemia in the treatment group,
and hypoglycemia has been associated with increased mortality [8, 20, 41, 42]. To date,
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neither intraoperative [43] nor postoperative [1] hyperglycemia has been associated with
worse neurodevelopmental outcomes after pediatric cardiac surgery. Furthermore,
experimental data exist suggesting that hyperglycemia may be protective to the immature
brain after hypoxic-ischemic injury [44]. However, it is also possible to hypothesize that
TGC could be neuroprotective: by improving post-operative recovery and shortening ICU
length of stay, a known risk factor for later functional limitation [45–47], TGC may be
beneficial. Comparing neurodevelopmental outcomes between the two treatment groups is
essential to determine the ultimate risk-benefit profile of this therapy.
Protocol Considerations
Our rationale for choosing the PID algorithm involved several factors [48]. The algorithm is
configured with a minimal number of parameters, had been specifically designed to work
with CGM, and worked well in pediatric critical care environments when implemented as a
paper-based protocol with Excel® spreadsheet verification [26]. This algorithm also holds
the future promise of possible direct linkage to the CGM system, creating closed-loop
monitoring and therapy, but such a system is yet to be developed.
This trial is the first to use CGM technology as an adjunct to intensive insulin therapy in any
critical care patient population. CGM technology has the potential to reduce the incidence of
hypoglycemia while targeting a normoglycemic BG range. Under ideal circumstances,
predictive alarms on CGM devices would alert study staff to impending hypoglycemia with
sufficient time to allow IV dextrose administration to prevent any fall in glucose below a
critical level. However, questions remain regarding the reliability and accuracy of these
devices to detect hypoglycemia, particularly under specific physiologic conditions [23, 24].
Though this technology requires improvement for optimal function, we believe that the
potential safety benefits warrant strong consideration for using CGM in all future trials of
TGC in pediatric patients.
Limitations
While it is typically desirable to achieve blinding of caregivers in a clinical trial, it would
not be practical or ethical in this study to do so and utilize a placebo infusion. Excess
placebo fluid delivery in the control group is possibly detrimental with no potential benefit.
Additionally, physicians and nurses caring for patients in the CICU must be aware of the
insulin infusion for safety reasons. The operating surgeon and anesthesiologist are blinded to
the randomization during the surgical procedure.
We did not protocolize intra- or post-operative practices such as bypass techniques, or post-
operative vasoactive and nutritional support that could impact the rate of hyperglycemia and
the likelihood of developing a nosocomial infection. This was done to promote adoption of
the study protocol by the surgical and CICU teams, and to increase generalizability of the
study findings by implementing the study protocol in “real-life” CICUs. Given that patients
were block randomized by center, between center practice differences will be equally
distributed between treatment arms.
The CHB and CSM CICUs are two of the highest volume pediatric cardiac surgery
programs in the United States, care for a high percentage of complex neonatal and infant
cases, and have dedicated cardiac intensive care physician and nursing staffs. How the
findings from these two CICUs will generalize to settings with different patient volumes,
case-mix, and resource availability remains to be determined. Subgroup analysis may clarify
some of these questions.
This study is powered to show a large difference between treatment groups for the primary
outcome (50% reduction in the rate of nosocomial infection per 1000 patient days in the
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CICU). Concurrent strategies to lower nosocomial infection rates in both units may decrease
the overall incidence of the outcome and reduce the study power. It is possible that smaller,
but clinically important differences may not be statistically significant, particularly when
analyzing secondary outcomes. In order to adequately power the study to detect smaller
differences between groups, the study sample size would be prohibitively large to complete
the trial within a reasonable period. There were no plans to readdress the power calculations
during the study to account for changes in the overall infection rate.
This study used bedside glucose meters used clinically at the study institutions. These were
considered state-of-the-art at the time the study was initiated, but have since been surpassed
by superior technology. International Organization for Standardization (ISO) guidelines
require an accuracy of +/−20%. Other more accurate options were available but not
incorporated into this study design due to prohibitive cost.
Conclusion
The care of infants and children who require cardiac surgery has advanced considerably in
the previous 30 years. As mortality rates have declined, CICU clinicians have become
focused on prevention of postoperative morbidity and improvement of long-term clinical
and functional outcomes. Previous literature suggests that pediatric cardiac surgical patients
may recognize benefit from TGC in the postoperative period, particularly in regard to
reduction of nosocomial infections. The SPECS study is designed to provide an unbiased
answer to the question of whether TGC, when delivered with the maximal safety of CGM, is
indeed beneficial to this high-risk population, and to define the associated risks of therapy.
Furthermore, at its conclusion this will be the largest cohort of pediatric cardiac surgical
patients ever prospectively enrolled in a clinical trial, and the knowledge acquired now and
in the future promises to greatly advance our understanding of the care of critically ill
children with cardiovascular disease.
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Figure 1.
Flow diagram for trial. CPB, cardiopulmonary bypass; OR, operating room; CICU, cardiac
intensive care unit; SSI, surgical site infection.
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Table 1
SPECS Trial subject inclusion and exclusion criteria
Inclusion criteria
• Patient ≤ 36 months of age, including neonates and infants, being taken to the operating room for cardiac surgery requiring CPB
with planned post-operative management in the CICU
Exclusion criteria
• Absence of an indwelling arterial, central venous, or transthoracic catheter that prevents access for blood draws or insulin infusion
• Patient with diabetes mellitus, type I or II
• Patient previously enrolled in SPECS during a separate CICU admission
• Patient who has already consented to participate in a competing clinical trial which the SPECS Data and Safety Monitoring Board
has not certified as a SPECS-compatible study
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Table 2
Trial secondary outcomes
Mortality
• ICU mortality, hospital mortality, 30-day mortality, and 1-year mortality
Cardiovascular/respiratory
• Average daily vasoactive-inotropic score/duration of vasoactive support
• Cardiac index on study days 2 and 5 (if ventilated)
• Time to normalization of arterio-venous saturation difference and lactate
• Time to first negative fluid balance
• Presence of tachyarrhythmias
• Duration of mechanical ventilation
Nutrition
• Daily caloric intake
• Total weight gain over hospitalization
• Resting energy expenditure on study days 2 and 5 (if ventilated)
• Nitrogen balance in for initial 24 hours post-operatively
• Urine 3-methyl histidine:creatine ratio
Immune
• White blood cell count on study day 3 and weekly
• C-reactive protein level on study day 3 and weekly
Endocrine
• Insulin-like growth factor binding protein-1 (IGF-BP1) levels on study day 2 and weekly
• Serum insulin on study day 2 and weekly
• Thyroid function tests and cortisol level on study day 2 and weekly
Neurologic
• Frequency of clinically-diagnosed seizures (includes EEG diagnosis)
Length of CICU and hospital admission
Neurodevelopment
EEG, electroencephalogram
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Table 3
Neurodevelopmental testing battery
Developmental domain 1-year assessment 3-year assessment
Cognition BSID-III: cognitive scale BSID-III: cognitive scale
Communication BSID-III: language scale BSID-III: language scale
Motor BSID-III: motor scale BSID-III: motor scale
Growth parameters Height, weight, head circumference Height, weight, head circumference
Adaptive behavior ABAS-II ABAS-II
Socio-emotional BITSEA BITSEA
Attention/behavior NA BASC-II
Developmental history ASQ ASQ
Socio-demographic data Family questionnaire Family questionnaire
BSID, Bayley Scales of Infant and Toddler Development (44); ABAS, Adaptive Behavior Assessment System (45); BITSEA, Brief Infant Toddler
Social and Emotional Assessment (46); BASC, Behavior Assessment Scale for Children (47); ASQ, Ages & stages questionnaire (48)
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